Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Kashef
K
Ijaz
Peter D
PD
McElroy
Thomas R
TR
Navin
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D006801:Humans; D008107:Liver Diseases / Q000517:prevention & control*; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects*; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin